RDUS earnings call for the period ending September 30, 2019.
News & Analysis: Radius Health
Shares push hire after the company reports earnings. Here's what investors need to know.
The biopharma announced its full-year 2017 earnings Thursday after the market closed.
Traders cheer after the company presents encouraging clinical data at a medical conference.
Shares popped after the company reported upbeat results from a phase 1 study.
A leading competitor's osteoporosis drug encountered serious side effects in a late stage trial.
Shares fall after the company reports a larger-than-expected quarterly loss, but exciting times lie ahead.
Shares swooned after the FDA announced that it needs more time to review the company's pending application.
The company's development stage drug RAD1901 reported positive phase 1 data, but shares fell anyway.
Shares are on the move after clinical data released on a competing compound showed that its drug might have a clinical edge.
Good news from the clinical-stage osteoporosis specialist couldn't overcome January's biotech beat down.